Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide.
An 8-year old child had a pelvic MYCN-nonamplified neuroblastoma (NB) with retroperitoneal nodal extension. Multi-modality therapy achieved complete remission (CR). Small recurrences confined to left supraclavicular nodes were treated with surgery alone at 4.9, 6.5, 7.5, 9.5, and 12.9 years from diagnosis. Monitoring through 12 months after the last resection showed CR. When she returned 34 months later (16.8 years from diagnosis), she had massive disease in the left neck and upper trunk, without osteomedullary metastases. Salvage therapy featured 11 cycles of temozolomide. She developed myelodysplastic syndrome with 45,XX,der(7)t(7;21) (p15;q11),-21 at age 24 and refused treatment; 19 months later she was transfusion-dependent but her NB remained in CR.
Kushner
Brian H
BH
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Laquaglia
Michael P
MP
Kramer
Kim
K
Modak
Shakeel
S
Cheung
Nai-Kong V
NK
D000293:Adolescent; D000328:Adult; D002471:Cell Transformation, Neoplastic / Q000139:chemically induced / Q000235:genetics*; D002648:Child; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D009362:Neoplasm Metastasis / Q000235:genetics / Q000473:pathology; D009447:Neuroblastoma / Q000150:complications / Q000235:genetics* / Q000473:pathology*; D012008:Recurrence; D000077204:Temozolomide
D003606:Dacarbazine; D000077204:Temozolomide